16980-89-5

Basic information

• Product Name: Bucladesine
• Synonyms: ibutyryl cyclic AMP sodium;Adenosine,N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate, sodiuM salt(1:1);Dibutyryl-cAMP sodium salt, >=98%;Adenosine 3?,5?-cyclic Monophosphate, N?,O;adenosine,n-(1-oxobutyl)-,cyclic3’,5’-(hydrogenphosphate)-2’-butanoate,m;bucladesinesodium;butyramide,n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-,cyclichydrogenphosphate,butyrate(ester),monosodiumsalt;dibutylcampsodiumsalt
• CAS NO: 16980-89-5
• Molecular Formula: C18H23N5NaO8P
• Molecular Weight: 491.37
• EINECS: 241-059-4
• Product Categories: Cyclic Nucleotide related
• Mol File: 16980-89-5.mol
• Article Data: 0

Chemical Properties

• Appearance: white/powder
• Storage Temp.: −20°C
• Solubility: H2O: 50 mg/mL
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month.
• Merck: 14,1463
• CAS DataBase Reference: Bucladesine(CAS DataBase Reference)
• NIST Chemistry Reference: Bucladesine(16980-89-5)
• EPA Substance Registry System: Bucladesine(16980-89-5)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 2
• RTECS: ES5055500
• F: 10-21
• Hazardous Substances Data: 16980-89-5(Hazardous Substances Data)

Usage

Description

Bucladesine sodium is a derivative of cyclic-AMP with cardiac stimulant and peripheral vasodilatory properties. It is reported to be useful in cardiac insufficiency, especially after heart surgery.

Originator

Daiichi Seiyaku; Seishin Seiyaku (Japan)

Uses

Bucladesine sodium is an analog of cyclic AMP that stimulates cAMP-dependent protein kinase. It has vasodilator properties and is used as a cardiac stimulant.

Definition

ChEBI: Bucladesine sodium is a 3',5'-cyclic purine nucleotide.

Application

N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt has been used:as a medium supplement for neural crest stem cells (NCSCs) differentiationas a component of thawing medium for cryopreserved human iPSC (induced pluripotent stem cell)-derived neuronsin serum-free Dulbecco′s modified eagle′s medium (DMEM) to induce astrocyte differentiation

Brand name

ACTOCIN

General Description

A cell-permeable cAMP analog that preferentially activates cAMP-dependent protein kinase (PKA). Causes an increase in the steady state level of parathyroid hormone-related peptide mRNA. Also acts as a Hh pathway antagonist. Shown to induce apoptosis in vascular smooth muscle cells.

Biochem/physiol Actions

Cell-permeable cAMP analog that activates cAMP dependent protein kinase (PKA).

References

1) Bartsch?et al.?(2003),?Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells; Biol. Chem.,?384?13212) Carranza?et al.?(1998),?Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells; J. Physiol.,?15?5113) Hei?et al.?(1991),?Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs; Mol. Pharmacol.,?39?2334) Imamura?et al.?(1998),?Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes; Proc. Natl. Acad. Sci. USA,?95?61395) Xia?et al.?(2016),?Transcriptional comparison of human induced and primary midbrain dopaminergic neurons; Sci. Rep.,?6?20270

Related news

Effect of Bucladesine (cas 16980-89-5) sodium on the plasma concentrations and urinary excretion of purine bases and uridine08/08/2019

To examine whether bucladesine sodium affects the plasma concentrations of purine bases (hypoxanthine, xanthine, and uric acid) and uridine, 100 mL of physiological saline containing bucladesine sodium (6 mg/kg weight) was administered intravenously to eight healthy subjects for 1 hour after ove...detailed

Effects of pentoxifylline and H-89 on epileptogenic activity of Bucladesine (cas 16980-89-5) in pentylenetetrazol-treated mice08/05/2019

The present study shows interactive effects of pentoxifylline (PTX) as a phosphodiesterase (PDE) inhibitor, H-89 as a protein kinase A (PKA) inhibitor and bucladesine (db-cAMP) as a cAMP agonist on pentylenetetrazol (PTZ)-induced seizure in mice. Different doses of pentoxifylline (25, 50, 100 mg...detailed